MetaCap

Aura Biosciences (AURA) vs Iambic Therapeutics (IAM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aura Biosciences is the larger company by market cap ($715.0 million vs $621.4 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AURA+8.36%IAM-30.67%
+30%-10%-50%
Oct 15, 20261 yearNov 20, 2026
AURA+12.62%IAM-44.94%
+20%-20%-61%
Oct 12, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AURA versus IAM key metrics
MetricAURAIAM
Share price$6.87$13.11
Market cap$714.99M$621.42M
1-day change-1.58%-8.06%
YTD return+26.06%—
1-year return+26.29%—
5-year return-69.63%—
EPS (TTM)$-1.59$-2.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-106.19M—
52-week high$9.54$25.00
52-week low$4.73$9.60
Distance from 52-week high-27.95%-47.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+141.63%+107.86%
Average volume847.22K714.92K
Shares outstanding104.07M47.40M
Employees113171
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Aura Biosciences

AURA stock →

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees

About Iambic Therapeutics

IAM stock →

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 171 employees

AURA vs IAM FAQ

Which is bigger, Aura Biosciences or Iambic Therapeutics?

Aura Biosciences (AURA) is larger, with a market capitalization of $714.99M compared with $621.42M for Iambic Therapeutics (IAM).

Are Aura Biosciences and Iambic Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons